This article was originally published in The Gray Sheet
Completes $12.5 mil. private placement of 4% convertible preferred stock. The funds strengthen the imaging and therapeutic product maker's financial position as it continues to boost marketing efforts for CEA-Scan (arcitumomab) in the U.S. and Europe, and for LeukoScan (sulesomab) in Europe. Plans for U.S. marketing of LeukoScan, pending FDA approval, are also under way. Subject to certain conditions, the firm has an option for up to an additional $7.5 mil. convertible preferred stock offering
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.